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Sympathetic stimulation of myocardial b-adrenergic recep-
tors (b-AR) represents the most powerful mechanism to
acutelyincreasecardiacoutput.Intheclinicalcourseofheart
failure,adrenergicstimulationinitiallyservestocompensate
for contractile dysfunction, but in the chronic hyperadren-
ergic state, it ﬁnally results in deterioration of cardiac
function and structure. This sympathetic dysregulation is
one of the best documented paradigms in cardiovascular
medicine and has been underscored by clinical trials dem-
onstrating remarkable beneﬁt from chronic b-AR blockade.
However, the positive effects of b-AR blockers appear
paradoxical since these drugs initially further compromise
contractile performance. The lesson learned is that b-AR
signaling represents a biologically ﬂexible system that
adapts quickly to overstimulation by a process termed
‘‘b-AR desensitization’’. This phenomenon is typical for
failing hearts and is regarded mainly as a protective mech-
anism of adaptation [4]. It involves decreased numbers of
myocardial b1-ARs as well as increased levels of G-protein-
coupled receptor kinases (GRK2) and inhibitory G-proteins
(Gi)[ 1]. However, more recently it became clear that
‘‘desensitization’’ is a reversible process and ‘‘resensitiza-
tion’’ occurs after catecholamine withdrawal. Accordingly,
b-AR blockers ‘‘resensitize’’ the failing heart and improve
exercise tolerance in patients and are associated with
normalization of b1-ARs, GRK2 and Gi levels in cardio-
myocytes. Besides the direct reduction of catecholamine-
mediated toxic effects on the heart normalization of b-AR
signaling might be an additional major beneﬁcial mecha-
nism of b-AR blockers. Thus, there is strong rationale for
therapeutic strategies aiming to either inhibit the b-AR
system or to restore its physiological sensitivity in heart
failure.
In addition to dysregulated b1-ARs, GRK2 and Gi, there
is a downregulation and deactivation of phosphatase-1-
inhibitor-1 (I-1), an intracellular phospho-protein that has
been recently implicated in b-AR desensitization [2, 5, 6].
Upon phosphorylation by PKA, I-1 acts as an ampliﬁer
element of b-AR signaling by preventing dephosphoryla-
tion of downstream targets by type-1 phosphatases (PP-1).
However, whether this ﬁnding should be viewed as a
protective or adverse response is controversial and thera-
peutic strategies that either inhibit endogenous I-1 activity
or increase its activity by expressing a constitutively active
I-1 mutant form (I-1c) are currently extensively
investigated.
In this issue of Basic Research in Cardiology, Chen
et al. [3] investigated the effects of transgenic heart-spe-
ciﬁc I-1c expression on apoptosis in the well-characterized
isoprenaline-infusion heart failure model. The authors
observed less cardiac apoptosis and preserved contractile
function in the transgenic I-1c hearts compared to wild
type. This was associated with changes in protein abun-
dance and phosphorylation level of several apoptosis-
related proteins. The overall conclusion from the present
study is consistent with previous work reporting that I-1c
transgenic mice exhibit better contractility and attenuated
deterioration of cardiac structure in models of chronic
cardiac pressure overload and ischemia/reperfusion injury,
respectively [9, 11].
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deleted mice (I-1 KO) were protected from catecholamine-
induced arrhythmias and progression to heart failure in a
very similar experimental approach setting [7]. Moreover,
again using the chronic catecholamine infusion model, we
observed exaggerated contractile dysfunction, ventricular
dilation and ﬁbrosis in conditional I-1c expressing mice
generated on an I-1 KO background. These changes were
reversible after shutting off I-1c expression by doxycycline
(Tet-Off-system) providing evidence for a direct causal
relationship [12]. Notably, the I-1c expressing mice
developed a cardiomyopathic phenotype with aging [8, 12].
Thus, this recent set of data suggests that inhibition of I-1
protects the heart, whereas the current and previous data
from the Kranias group support the idea of AAV-mediated
I-1c expression as a new therapeutic approach in heart
failure. At present it is not clear how these apparently
opposing concepts can be integrated.
Despite almost identical I-1c expression levels
(*25-fold) and very similar experimental conditions
(14 days 30 vs. 50 mg/kg/day in this study), the two mice
studies dealing with the role of I-1c in chronic catechol-
aminergic stress differ in important aspects. First, the
genetic background in our study was C57Bl/6J, whereas it
was FVB/N in the present study. It is well known that such
strain differences can give rise to very different results.
Second, different environmental factors in mouse hus-
bandry could contribute. A straightforward solution would
be to analyze the ‘‘other’’ mouse-model in the own labo-
ratory with the corresponding backgrounds and vice versa.
Third, and maybe most importantly, Chen et al. [3]
expressed I-1c on top of endogenous I-1, whereas we
expressed I-1c on an I-1 knockout background, i.e. in the
absence of endogenous I-1. The reasoning was that, in the
presence of endogenous I-1, the less potent (*8-fold
higher IC50 [12]) but stoichiometrically dominating 25-fold
overexpressed I-1c would compete for binding to PP-1 with
both phosphorylated (active) and non-phosphorylated
(inactive) I-1 [10]. Whereas the former action would
dampen the maximal effect of catecholamines (making I-1c
a partial antagonist), the latter would lead to increased
basal activity, making I-1c a partial agonist. Thus, the PP-
1-inhibiting effect of I-1c will depend on endogenous I-1
levels and its phosphorylation status and thus on the degree
of cellular catecholaminergic stress. We considered this a
complicated situation, but it may indeed explain why our
results differ from that of the present and former studies.
Taken together, despite the substantial advance in our
understanding of the role of this small b-AR ampliﬁer in
the heart, it is still unclear whether I-1 is a promising
therapeutic target in heart failure and if yes, whether its
activity/amount should be increased or decreased. In order
to determine its real therapeutic value in heart failure,
pharmacological agents are likely needed to modulate I-1
activity in the context of preexisting heart failure.
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